ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,912.39
0.19%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Vanda Pharmaceuticals Inc (VNDA)

  7. Vanda Pharmaceuticals Inc (VNDA) News

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VNDA
DateTimeSourceHeadlineSymbolCompany
09/05/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VNDAVanda Pharmaceuticals Inc
09/05/202412:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202421:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
08/05/202421:01PR Newswire (US)Vanda Pharmaceuticals Reports First Quarter 2024 Financial ResultsNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202421:51Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
07/05/202416:16PR Newswire (US)Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
30/04/202421:30PR Newswire (US)Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024NASDAQ:VNDAVanda Pharmaceuticals Inc
25/04/202413:05GlobeNewswire Inc.Shareholder Capital Delivers Letter to Independent Members of the Board of Vanda PharmaceuticalsNASDAQ:VNDAVanda Pharmaceuticals Inc
23/04/202400:13PR Newswire (US)Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA LitigationNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202415:21PR Newswire (US)Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights PlanNASDAQ:VNDAVanda Pharmaceuticals Inc
17/04/202414:02PR Newswire (US)Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future PakNASDAQ:VNDAVanda Pharmaceuticals Inc
03/04/202415:25AllPennyStocks.comBiotech Catches Major Premarket Bid Following FDA ApprovalNASDAQ:VNDAVanda Pharmaceuticals Inc
02/04/202423:10PR Newswire (US)Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I DisorderNASDAQ:VNDAVanda Pharmaceuticals Inc
07/03/202421:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:47Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
06/03/202412:00PR Newswire (US)Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of InsomniaNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202402:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202402:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202402:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202402:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
05/03/202402:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/02/202421:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/02/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/02/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/02/202421:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
21/02/202421:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VNDAVanda Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:VNDA

Your Recent History

NYSE
IQV
IQVIA
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved